Funnily enough they said the same about covid ards last year.
We are targeting the sickest of the sick where our cells are proven (In phase 2 trials) to be most effective. Fast forward to phase 3 trial results, we didn't reach our primary endpoint goals as our cells were given too late. They need to be given as early as possible to be most effective.
I'm expecting by end of 2021 for the team to say our cells as most effective when dosed 365 days a year.
USD573M in retained losses and a less than great 2020!. 2021 a year that cannot get worse, page-8
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.52 |
Change
-0.060(2.33%) |
Mkt cap ! $3.225B | |||
| Open | High | Low | Value | Volume |
| $2.58 | $2.61 | $2.50 | $12.63M | 4.955M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8366 | $2.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.53 | 8780 | 4 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |